Chang Hsin-Hou, Liou Yu-Shan, Sun Der-Shan
Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan.
Tzu Chi Med J. 2021 Oct 21;34(3):270-275. doi: 10.4103/tcmj.tcmj_98_21. eCollection 2022 Jul-Sep.
Hematopoietic stem cell (HSC) transplantation has been used to treat hematopoietic diseases for over 50 years. HSCs can be isolated from bone marrow (BM), umbilical cord blood, or peripheral blood. Because of lower costs, shorter hospitalization, and faster engraftment, peripheral blood has become the predominant source of HSCs for transplantation. The major factors determining the rate of successful HSC transplantation include the degree of human leukocyte antigen matching between the donor and recipient and the number of HSCs for transplantation. Administration of granulocyte colony-stimulating factor (G-CSF) alone or combined with plerixafor (AMD3100) are clinical used methods to promote HSC mobilization from BM to the peripheral blood for HSC transplantations. However, a significant portion of healthy donors or patients may be poor mobilizers of G-CSF, resulting in an insufficient number of HSCs for the transplantation and necessitating alternative strategies to increase the apheresis yield. The detailed mechanisms underlying G-CSF-mediated HSC mobilization remain to be elucidated. This review summarizes the current research on deciphering the mechanism of HSC mobilization.
造血干细胞（HSC）移植用于治疗造血疾病已有50多年历史。造血干细胞可从骨髓（BM）、脐带血或外周血中分离获得。由于成本较低、住院时间较短且植入更快，外周血已成为移植用造血干细胞的主要来源。决定造血干细胞移植成功率的主要因素包括供体与受体之间人类白细胞抗原匹配程度以及移植所用造血干细胞的数量。单独使用粒细胞集落刺激因子（G-CSF）或与普乐沙福（AMD3100）联合使用，是临床上用于促进造血干细胞从骨髓动员至外周血以进行造血干细胞移植的方法。然而，相当一部分健康供体或患者可能对G-CSF的动员效果不佳，导致用于移植的造血干细胞数量不足，因此需要采取替代策略来提高单采产量。G-CSF介导的造血干细胞动员的详细机制仍有待阐明。本综述总结了目前关于解读造血干细胞动员机制的研究。
